Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records.
Sun VH, Heemelaar JC, Hadzic I, Raghu VK, Wu CY, Zubiri L, Ghamari A, LeBoeuf NR, Abu-Shawer O, Kehl KL, Grover S, Singh P, Suero-Abreu GA, Wu J, Falade AS, Grealish K, Thomas MF, Hathaway N, Medoff BD, Gilman HK, Villani AC, Ho JS, Mooradian MJ, Sise ME, Zlotoff DA, Blum SM, Dougan M, Sullivan RJ, Neilan TG, Reynolds KL. Sun VH, et al. Among authors: leboeuf nr. J Clin Oncol. 2024 Dec 10;42(35):4134-4144. doi: 10.1200/JCO.24.00326. Epub 2024 Sep 3. J Clin Oncol. 2024. PMID: 39226489
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. Townsend EC, et al. Among authors: leboeuf nr. Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. Cancer Cell. 2016. PMID: 27479034 Free article. No abstract available.
Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service.
Abu-Shawer O, Singh P, Yenulevich E, Brito A, Ni J, Abdulnour RE, Grover S, Manos M, Bowling P, LeBoeuf NR, Ott P, Stephen Hodi F, Jacobson J, Rahma O. Abu-Shawer O, et al. Among authors: leboeuf nr. J Immunother Cancer. 2020 Aug;8(2):e000992. doi: 10.1136/jitc-2020-000992. J Immunother Cancer. 2020. PMID: 32817360 Free PMC article.
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA, Betof Warner A, Brastianos PK, Cho TA, Clardy SL, Cohen JV, Dietrich J, Dougan M, Doughty CT, Dubey D, Gelfand JM, Guptill JT, Johnson DB, Juel VC, Kadish R, Kolb N, LeBoeuf NR, Linnoila J, Mammen AL, Martinez-Lage M, Mooradian MJ, Naidoo J, Neilan TG, Reardon DA, Rubin KM, Santomasso BD, Sullivan RJ, Wang N, Woodman K, Zubiri L, Louv WC, Reynolds KL. Guidon AC, et al. Among authors: leboeuf nr. J Immunother Cancer. 2021 Jul;9(7):e002890. doi: 10.1136/jitc-2021-002890. J Immunother Cancer. 2021. PMID: 34281989 Free PMC article.
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.
Tang K, Seo J, Tiu BC, Le TK, Pahalyants V, Raval NS, Ugwu-Dike PO, Zubiri L, Naranbhai V, Carrington M, Gusev A, Reynolds KL, LeBoeuf NR, Asgari MM, Kwatra SG, Semenov YR. Tang K, et al. Among authors: leboeuf nr. JAMA Dermatol. 2022 Feb 1;158(2):189-193. doi: 10.1001/jamadermatol.2021.5476. JAMA Dermatol. 2022. PMID: 35019948 Free PMC article.
IL-32 Supports the Survival of Malignant T Cells in Cutaneous T-cell Lymphoma.
Yu KK, Smith NP, Essien SV, Teague JE, Vieyra-Garcia P, Gehad A, Zhan Q, Crouch JD, Gerard N, Larocca C, Wolf P, LeBoeuf NR, Tawa M, Kupper TS, Villani AC, Clark RA. Yu KK, et al. Among authors: leboeuf nr. J Invest Dermatol. 2022 Aug;142(8):2285-2288.e2. doi: 10.1016/j.jid.2022.01.009. Epub 2022 Feb 7. J Invest Dermatol. 2022. PMID: 35143819 Free PMC article. No abstract available.
Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Bui AN, Tyan K, Giobbie-Hurder A, Klein IA, Manos MP, Zubiri L, Reynolds K, Grover S, Weinhouse GL, Ott PA, LeBoeuf NR, Rahma O. Bui AN, et al. Among authors: leboeuf nr. J Immunother Precis Oncol. 2021 May 14;4(2):35-44. doi: 10.36401/JIPO-20-34. eCollection 2021 May. J Immunother Precis Oncol. 2021. PMID: 35663537 Free PMC article.
Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective study.
Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, Semenov YR, LeBoeuf NR, Reynolds KL, Dewan AK, Chen ST. Asdourian MS, et al. Among authors: leboeuf nr. J Am Acad Dermatol. 2023 Feb;88(2):474-476. doi: 10.1016/j.jaad.2022.06.025. Epub 2022 Jun 17. J Am Acad Dermatol. 2023. PMID: 35724890 Free PMC article. No abstract available.
156 results